Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.

NEW YORK (TheStreet) -- Did you miss last night's "Mad Money" on CNBC? If so, here are Jim Cramer's top takeaways for today's trading.

HELE data by YCharts

Image placeholder title

Helen of Troy (HELE) - Get Report : When a company you have confidence in hits a speed bump, have some conviction and stick with it. Often times, you'll be rewarded handsomely.

That was certainly the case with Helen of Troy, the consumer packaged goods company that makes such brands as Oxo kitchen gadgets, Pur water filters, Pert shampoo and Vicks health and wellness items.

Cramer recommended Helen of Troy earlier this year and was seeing some nice gains when the company missed earnings on July 9, sending shares down a sharp 10%. But Cramer reiterated his recommendation shortly thereafter, noting that the analysts had simply gotten ahead of themselves and no company could've met the expectations they had set.

Flash forward to last Thursday, when Helen delivered a stunning 41-cents-a-share earnings beat. The stock is now up over 18% from its July lows.

Cramer reminded viewers that Helen breathes new life into tired brands and is a master at innovating and cutting costs. The stock still has a lot more room to run, he said, as shares trade at just 17.6 times earnings, which is still less than its peers. Don't forget that Helen of Troy derives 80% of its sales domestically, so is not hostage to overseas woes.

BMRN data by YCharts

Image placeholder title

BioMarin Pharmaceuticals (BMRN) - Get Report : For his "Executive Decision" segment, Cramer sat down with JJ Bienaime, CEO of orphan drug maker BioMarin.

Bienaime commented on his company's recent win in a patent dispute with Sarepta Therapeutics (SRPT) - Get Report , calling the victory an important win for the protection of the company's intellectual property.

Bienaime also commented on the recent controversy surrounding drug pricing. He said that BioMarin is not in the business of repurposing old molecules and is instead developing important treatments for lethal diseases that have no other treatments and that would cost the healthcare system far more to manage over the long term.

For many of BioMarin's treatments, getting diagnosed early is important, Bienaime said, that's why his company is helping muscular dystrophy patients determine which mutation of the disease they have as early as possible so they can begin treatment.

ETP data by YCharts

Image placeholder title

Energy Transfer Partners (ETP) : In today's tricky energy market, investors need stocks they can live with. That's why Energy Transfer Partners, with its 9% yield, remains his favorite pipeline master limited partnership and a stock which he owns for his charitable trust, Action Alerts PLUS.

Cramer said that Energy Transfer Equity's (ETE) acquisition of Williams Energy (WMB) - Get Report for $38 billion will be a game changer for for ETP, as it will give the company a national footprint and turn it into a powerhouse.

Cramer reminded viewers that ETP is not an oil producer like Linn Energy (LINE) , nor is it levered to the price of crude. That makes the decline in Energy Transfer's shares a huge buying opportunity and makes it a "must own" name.

To read a full recap of "Mad Money" on CNBC, click here.

To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.

At the time of publication, Cramer's Action Alerts PLUS had a position in ETP.